Real World Effectiveness of Ustekinumab and Vedolizumab in TNF-exposed Pediatric Patients with Ulcerative Colitis, May 2024 JPGN

Clinical outcomes and cost savings of a nonmedical switch to a biosimilar in children/young adults with inflammatory bowel disease, March 2024 JPGN

Key:

Complete
Failed
Available
Locked
CME Requirements and Learning Objectives: Real World Effectiveness of Ustekinumab and Vedolizumab in TNF-exposed Pediatric Patients with Ulcerative Colitis, May 2024 JPGN
Open to download resource.
Open to download resource. Real World Effectiveness of Ustekinumab and Vedolizumab in TNF-exposed Pediatric Patients with Ulcerative Colitis, May 2024 JPGN
You must register to access.
Real World Effectiveness of Ustekinumab and Vedolizumab in TNF-exposed Pediatric Patients with Ulcerative Colitis, May 2024 JPGN
Open to download resource.
Open to download resource. Real World Effectiveness of Ustekinumab and Vedolizumab in TNF-exposed Pediatric Patients with Ulcerative Colitis, May 2024 JPGN
You must register to access.
Post Test: Real World Effectiveness of Ustekinumab and Vedolizumab in TNF-exposed Pediatric Patients with Ulcerative Colitis, May 2024 JPGN
3 Questions  |  Unlimited attempts  |  2/3 points to pass
3 Questions  |  Unlimited attempts  |  2/3 points to pass Real World Effectiveness of Ustekinumab and Vedolizumab in TNF-exposed Pediatric Patients with Ulcerative Colitis, May 2024 JPGN
You must register to access.
Evaluation: Real World Effectiveness of Ustekinumab and Vedolizumab in TNF-exposed Pediatric Patients with Ulcerative Colitis. May 2024 JPGN
14 Questions
14 Questions Real World Effectiveness of Ustekinumab and Vedolizumab in TNF-exposed Pediatric Patients with Ulcerative Colitis, May 2024 JPGN
You must register to access.
Certificate: Real World Effectiveness of Ustekinumab and Vedolizumab in TNF-exposed Pediatric Patients with Ulcerative Colitis, May 2024 JPGN
1.00 credit  |  Certificate available
1.00 credit  |  Certificate available Real World Effectiveness of Ustekinumab and Vedolizumab in TNF-exposed Pediatric Patients with Ulcerative Colitis, May 2024 JPGN
You must register to access.